A5016840607- Advanced Radiotherapy Techniques
- Lung Cancer Diagnosis and Treatment
- Radiation Therapy and Dosimetry
- Lung Cancer Treatments and Mutations
- Advances in Oncology and Radiotherapy
- Head and Neck Cancer Studies
- Lung Cancer Research Studies
- Brain Metastases and Treatment
- Endometrial and Cervical Cancer Treatments
- Radiation Dose and Imaging
- Effects of Radiation Exposure
- Radiology practices and education
- Lymphoma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Ovarian cancer diagnosis and treatment
- Radiomics and Machine Learning in Medical Imaging
- CAR-T cell therapy research
- Ultrasound and Hyperthermia Applications
- Global Cancer Incidence and Screening
- Pancreatic and Hepatic Oncology Research
- Colorectal and Anal Carcinomas
- Head and Neck Surgical Oncology
- Meningioma and schwannoma management
- Diversity and Career in Medicine
University Hospitals Seidman Cancer Center
2023-2025
University of Maryland, Baltimore
2015-2024
University Hospitals of Cleveland
2023-2024
Case Western Reserve University
2023-2024
University of Baltimore
2018-2024
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
2017-2023
U-M Rogel Cancer Center
2019-2022
University of Maryland Medical Center
2016-2020
University of Maryland, College Park
2020
Collaborative Group (United States)
2020
Purpose Local failure rates after radiation therapy (RT) for locally advanced non–small-cell lung cancer (NSCLC) remain high. Consequently, RT dose intensification strategies continue to be explored, including hypofractionation, which allows acceleration that could potentially improve outcomes. The maximum-tolerated (MTD) with dose-escalated hypofractionation has not been adequately defined. Patients and Methods Seventy-nine patients NSCLC were enrolled on a prospective single-institution...
Abstract Background Neutrophil-lymphocyte ratio (NLR) is a measure of systemic inflammation that appears prognostic in localized and advanced non-small cell lung cancer (NSCLC). Increased portends poorer prognosis patients. We hypothesized low NLR at diagnosis associated with improved overall survival (OS) locally NSCLC (LANSCLC) Patients Methods Records from 276 patients stage IIIA IIIB treated definitive chemoradiation or without surgery between 2000 2010 adequate data were retrospectively...
Abstract Background Hypofractionated-SRS (HF-SRS) may allow for improved local control and a reduced risk of radiation necrosis compared to single-fraction-SRS (SF-SRS). However, data comparing these two treatment approaches are limited. The purpose this study was compare clinical outcomes between SF-SRS versus HF-SRS across our multi-center academic network. Methods Patients treated with or brain metastasis from 2013 2018 5 oncology centers were retrospectively reviewed. dosing...
Virtual learning in radiation oncology (RO) has potential to reach medical students who otherwise lack access RO exposure or mentorship at their school. This study characterized the relative effectiveness of different methods promoting virtual education content, inform future efforts expand education. A 4-part "Oncology Series for Medical Students" was developed emulate an interest group (OIG). All academic department chairs and residency program directors were asked engage respective Dean's...
Abstract Locally advanced rectal cancers are treated with neoadjuvant chemoradiation therapy followed by surgery. In a minority (~20%) of patients, no tumor is present at the time surgery; these patients complete pathologic response (path CR ) to have better treatment outcomes. Unfortunately, inherent radioresistance colorectal cancer ( CRC cells dictates that majority do not achieve path . Efforts improve odds fueled search for novel, relatively less‐toxic radiosensitizers distinct...
We report the safety data from first multicenter phase 1 trial investigating use of hypofractionated proton therapy with concurrent chemotherapy for patients stage II or III non-small cell lung cancer.From 2013 through 2018, newly diagnosed cancer were enrolled in a clinical evaluating increasing dose-per-fraction therapy. This was stepwise 5 + 2 dose-intensification protocol following dose arms: (1) 2.5 GyRBE per fraction to 60 GyRBE; (2) 3.0 (3) 3.53 60.01 and (4) 4.0 GyRBE. A arm...
Summary In the relapsed/refractory setting for treatment of large B‐cell lymphoma (LBCL), chimeric antigen receptor T‐cell (CAR‐T) therapy has emerged as an effective modality. Patients often have aggressive disease that requires prompt in form bridging (BT) stabilisation while CAR‐T cells are manufactured. ( n = 75) undergoing infusion LBCL at our institution were identified. A total 52 (69·3%) received BT and 23 (30·7%) no (NBT). modalities included systemic (SBT) 28 patients, radiation...